Key result
Low molecular weight heparin was associated with higher healthcare resource utilization and costs for VTE treatment in cancer patients relative to warfarin and rivaroxaban.
Why the study?
Does LMWH compared to warfarin and rivaroxaban affect healthcare resource utilization and costs in cancer patients with VTE?
Does LMWH compared to warfarin and rivaroxaban affect healthcare resource utilization and costs in cancer patients with VTE?
In cancer patients with VTE, treatment with LMWH is associated with higher healthcare resource utilization and costs compared to warfarin and rivaroxaban.
Healthcare resource use and costs associated with VTE treatment in cancer patients are highest with LMWH relative to warfarin and rivaroxaban.
No takes yet. Share an insight, caveat, or question.
Streiff et al. (2019) studied this question. Low molecular weight heparin was associated with higher healthcare resource utilization and costs for VTE treatment in cancer patients relative to warfarin and rivaroxaban.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: